Tooth loss in breast cancer patients: a comparison between tamoxifen-treated and non-treated patients

• Jane Janet Julca-Baltazar ^[1] ; Angel Seven Asmat-Abanto ^[2] ; Andy Ray Pantoja-Lázaro ^[3] ; Ana Paula Gorritti-Rubio ^[4] ; Carlos Alberto Minchón-Medina ^[5]
  1. [1] Universidad Privada Antenor Orrego

     Universidad Privada Antenor Orrego

     Provincia de Trujillo, Perú

     
  2. [2] Orcid: 0000-0001-5726-6692. Doctor in Stomatology. Specialist in Periodontics. Professor of Human Medicine Study Program. Antenor Orrego Private University, Trujillo, Peru; Professor of Stomatology Study Program. Antenor Orrego Private University, Trujillo, Peru
  3. [3] Specialist in Oncological Surgery. Sub-specialist in Oncological Surgery of Breasts, Skin and Soft Tissues. Chief of the Department of Oncological Surgery of Breasts and Soft Tissue Tumors of the Regional Institute of Neoplastic Diseases IREN Norte “Dr. Luis Pinillos Ganoza”, Trujillo, Peru
  4. [4] Specialist in Medical Oncology. Assistant physician of the Medical Oncology Service of the High Complexity Hospital "Virgen de la Puerta"; Professor of Human Medicine Study Program. Antenor Orrego Private University, Trujillo, Peru
  5. [5] Doctor in Public Health, Postgraduate Professor. Department of Statistics, Trujillo National University, Trujillo, Peru

  Mostrar afiliaciones +
• Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 29, Nº. 4 (July), 2024
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Tooth loss (TL) affects quality of life and general health. The literature suggesting that tamoxifen treatment in patients with breast cancer (BC) could be associated with alterations in oral health, increasing the risk of TL, is still scarce. This work aimed to determine the relationship between TL and tamoxifen consumption in patients with BC.

    This cross-sectional observational study was carried out from July to September 2023 in the medical oncology services of the “Virgen de la Puerta” - ESSALUD High Complexity Hospital and “Dr. Luis Pinillos Ganoza” - IREN Norte - Regional Institute of Neoplastic Diseases, in Trujillo - Peru. Overall, 200 adult patients diagnosed with BC were evaluated, of which 100 consumed tamoxifen and 100 did not. Inter- and intra-rater reliability was determined with respect to TL, resulting in intra-class correlation values RHO = 0.971 and interclass RHO = 0.938. The oncologist of the corresponding service performed BC diagnosis and stage. Poisson regression was used to analyze results with a significance level of p<0.05.

    No relationship was found between TL and tamoxifen consumption in patients with breast cancer (p= 0.221); however, greater TL was observed in women who consumed tamoxifen for more than one year compared to those who did not use it (p=0.025) and in older adult women compared to young women (p=0.030).

    There is a relationship between TL and time of use of tamoxifen in patients with BC, concluding that patients who consumed tamoxifen for more than one year had greater TL than those who did not. Furthermore, no relationship was found between TL and cancer stages, but there was greater TL in older adult patients and also in those who consumed tamoxifen and did not receive chemotherapy or radiotherapy.